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Turning a pathogen protein into a
therapeutic tool for sepsis
Tineke Vanderhaeghen1,2, Charlotte Wallaeys1,2 & Claude Libert1,2,*
Sepsis causes unacceptably high amounts
of deaths worldwide. It is a huge unmet
medical need, and new therapeutic inter-
ventions for sepsis and septic shock are
urgently needed. By studying the mecha-
nism by which a bacterial protein under-
mines the inflammatory function of
macrophages, Kim et al, in the last issue of
EMBO Molecular Medicine, have developed
a new therapeutic protein drug, which
appears to have very promising protective
activities in a well-validated and aggres-
sive polymicrobial sepsis model in mice.
The chimeric protein is thought to limit
macrophage inflammation while activat-
ing phagocytosis, and so, it hits two
macrophage pathways at once.
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A ccording to a recent paper, sepsisyearly hits up to 49 million people,killing 11 million of them (Rudd
et al, 2020). This means that almost one in
five deaths on the planet are due to sepsis
and that, on a global scale, the risk of dying
when diagnosed with sepsis is 22%. These
staggering numbers underscore the 2017 call
of WHO to consider sepsis as a top-priority
unmet medical need (Reinhart et al, 2017).
Despite 78% of sepsis patients recover, many
of them retain life-long disabilities, e.g.,
cognitive problems and depression. Resusci-
tation, organ function support, antibiotics,
and infection control form the cornerstones
of today’s treatment (Van Der Poll et al,
2017). The need for innovative therapeutics,
which are applicable in the most remote
corners of the planet, is urgent and high.
The majority of sepsis cases results from
bacterial infections. Only about a dozen
infectious bacteria cover most of the cases,
and considerable overlap exists between dif-
ferent sepsis forms, e.g., between peritonitis
and pneumonia. Bacteria causing sepsis
include Gram-negative and Gram-positive
bacteria, mostly aerobics (Van Der Poll et al,
2017). The generation of sepsis-preventing
strategies, based on vaccination, has proven
to be difficult, but not impossible. For exam-
ple, several vaccines against Streptococcus
pneumoniae are commercially available
(Kaplonek et al, 2018). Besides, the develop-
ment of therapeutic, inhibitory monoclonal
antibodies directed against bacterial antigens
is gaining interest. These strategies are
directed toward the support of the immune
system of the (potentially) infected patient.
The reason why the immune system
needs help to overcome sepsis may lay in
the relatively slow mode of action of the
adaptive immune response. However, sepsis
is typically an acute and severe infection,
e.g., starting from an intestinal perforation
(Van Wyngene et al, 2018). Given this acute-
ness, it is more up to the innate immune
response to overcome the first days of
sepsis. It is generally believed that macro-
phages and neutrophils are first in line to
detect and clear the infection. They develop
an acute inflammatory response, are
attracted to the site of infection, and will kill
invaders via the production of toxins (e.g.,
defensins, reactive oxygen intermediates)
and phagocytosis. Despite these mechanisms
are efficient and fast, they are associated
with collateral damage to host cells and
tissues, which may prove to be fatal (Venet
& Monneret, 2018). However, the develop-
ment of drugs that guide this innate immune
response through this mine field, while
remaining focused and efficient, would be
beneficial. This is the merit of the paper of
Kim et al, in the last issue of EMBO Molecu-
lar Medicine (Kim et al, 2020).
The authors focused their attention on a
well-known protein produced by Mycobac-
terium tuberculosis, the pathogenic bacteria
causing tuberculosis. This protein, the
16 kDa big Rv2626c, has been studied exten-
sively because it is known to have a strong
impact on host macrophages (Bashir et al,
2010). Exclusively in the mouse model, Kim
et al show that the protein, when presented
to macrophages, enters the cells via a Toll-
like receptor (TLR)2-dependent pathway. It
is slightly inflammatory, as it induces some
inflammatory cytokines. However, Rv2626c
is strongly reducing the inflammation
induced by lipopolysaccharides (LPS),
which are cell wall components of Gram-
negative bacteria, which activate macro-
phages via the TLR4 route. Once in the cells,
Rv2626c was found to interact with several
interesting proteins, including Ripk1 (recep-
tor-interacting serine–threonine kinase 1)
and TRAF6 (TNF receptor-associated factor
6). The interaction of Rv2626c with TRAF6
is the main focus of the paper. The interac-
tion of Rv2626c and Ripk1 could also be of
great interest, since Ripk1 is essential in
progression of inflammation and cell death.
TRAF6 is known as a scaffold protein, which
integrates several signaling molecules and
allows them to interact in complexes. TRAF6
itself becomes labeled with ubiquitin chains,
which are coupled in a K63 linear way
(meaning that ubiquitin monomers are
coupled to the lysin on position 63 of the
previous ubiquitin monomer). This linear
K63-linked polyubiquitination is essential
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for the activation of the pro-inflammatory
transcription factor NF-jB. Kim et al show
that Rv2626c inhibits the formation of this
K63 ubiquitin chain on TRAF6. Since Ripk1
is also K63-ubiquitinated, the impact of
Rv2626c on this chain would be great to
know. By a number of elegant experiments,
they also pinpoint a stretch of 9 amino acids
of the Rv2626c protein, which are key in the
binding and muting of TRAF6.
Kim et al developed a new recombinant
chimeric protein by first linking 5 copies of
the 9 amino acids of Rv2626c that bind to
TRAF6 to a cell-penetrating peptide on the
N-terminal side via a short linker. This was
then fused to 10 copies of the Tuftsin motif
of 4 amino acids (TKPR) on the C-terminal
side, leading to the generation of a protein
of 101 amino acids, called rRv2626c-CA.
This protein penetrates cells, inhibits
TRAF6, and is suspected to have the phago-
cytosis activating effects of the Tuftsin
motif.
When added to macrophages, rRv2626c-
CA shows TRAF6 inhibition and anti-in-
flammatory effects, when cells are stimu-
lated with LPS (Fig 1). Interestingly, this
protein has very robust protective effects in
a polymicrobial sepsis mouse model,
namely the cecal ligation and puncture
(CLP) model. This highly validated model
causes a lethal septic peritonitis, very simi-
lar as in humans (Dejager et al, 2011). The
attractive aspects of this therapy are its
quick establishment (by 4 injections at 0, 6,
12 and 24 h after CLP initiation), its dose
responsiveness, and turning an LD90 sepsis
into an LD10, leading to a significant protec-
tion in the CLP model. When the therapeu-
tic protein is labeled, it accumulates in
several tissues, almost exclusively in
macrophages, which, by means of the
protein, have undergone a clear shift
toward the M2 type of macrophages.
rRv2626c-CA has a significant therapeutic
impact in the CLP model. However, before
moving into human sepsis, there is more
work to be done. It will be essential to show
safety of the therapy, but also to show thera-
peutic effects in other mouse models of
sepsis, predominantly in pneumonia models
and urogenital and brain sepsis models.
Also, therapeutic effects in larger pre-clinical
models, such as pigs, will be mandatory.
Furthermore, the real mechanism underlying
the therapy is not clear. The macrophages of
the protected animals indeed express some
typical markers associated with phagocyto-
sis, but the authors have not shown that
rRv2626c-CA stimulates phagocytosis of
particles or bacteria. Also, the reason why
the protein appears to hit macrophages pref-
erentially is not clear. These and other stud-
ies, e.g., using TRAF6-deficient mice, would
be most welcome to study this mechanism
in more depth.
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Figure 1. Sepsis is associated with bacteria, which stimulate phagocytes via several different surface
molecules, including Toll-like receptors.
These receptors will activate inflammatory transcription factors, the best characterized being NF-jB. TRAF6
is a central scaffold regulatory molecule. Inflammation, which is aimed to stimulate the macrophages to kill
the bacteria, move toward them, and engulf them by phagocytosis, but it causes also collateral damage to
host cells and tissues, causing death of the host. The rR2626c-CA protein can be sneaked into cells thanks to
a cell permeability peptide, dampens TRAF6 by a TRAF6-binding part, thereby limiting inflammation, but at
the same time activates chemotaxis and phagocytosis, thanks to a Tufts peptide repeat.
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